Table 1.
Summary of demographic and defining characteristics of the patients of the included clinical trials
| Author (year) | Diagnosis | Treatment | No. of patients | Median age; years (range) | Female (%) | LSMM (%) | Estimation of sarcopenia | Endpoints |
|---|---|---|---|---|---|---|---|---|
| Ando (2020) | AML, MDS | Allo‐HCT | 125 | 47 (16–65) | 52 (41.6%) | 52 (41.6%) | CT at L3 level | OS/PFS/NRM |
| Armenian (2019) | ALL, AML, and MDS | Allo‐HCT | 859 | 51 (18–74) | 395 (50.0%) | 290 (33.8%) | CT at L3 level | OS/NRM |
| Armenian (2020) | HL and NHL | Allo‐HCT | 320 | 53.3 (18.5–78.1) | 122 (38.1%) | 109 (34.1%) | CT at L3 level | OS |
| Besutti (2021) | DLBCL | R‐CHOP | 116 | 63.7 a | 56 (48.3%) | NR | CT at L3 level | OS/PFS |
| Burkart (2019) | DLBCL, MCL, and BL | Chemotherapy | 109 | 64 (44.8–74.8) | 56 (51.4%) | 65 (59.6%) | CT or PET/CT at L3 level | OS |
| Camus (2014) | DLBCL | R‐CHOP | 80 | 78 (70–88) | 45 (56.3%) | 44 (55%) | CT at L3 level | OS/PFS |
| Chu (2017) | DLBCL | R‐CHOP | 224 | 62 (21–88) | 99 (44.2%) | NR | CT at L3 level | OS/PFS |
| Chu (2015) | FL | Chemotherapy | 145 | 57 (29–83) | 65 (44.8%) | NR | CT at L3 level | OS |
| Go (2016) | DLBCL | R‐CHOP | 187 | 61.6 | 75 (40.1%) | 46 (24.6%) | CT at T4 level | OS/PFS |
| Iltar (2021) | DLBCL | R‐CHOP | 120 | 59.1 (52–68) | 54 (45.0%) | 65 (54.2%) | CT at psoas level | OS/PFS |
| Jung (2021) | AML | Chemotherapy, HMA | 96 | 58 (18–84) | 12 (12.5%) | 37 (38.5%) | CT or PET/CT at L1 level | OS/PFS |
| Lanic (2014) | DLBCL | R‐CHOP | 83 | 78 (70–95) a | 46 (56.1%) | 45 (54.9%) | CT at L3 level | OS/PFS |
| Lin (2020) | HL and NHL | Allo‐HCT | 146 | NR | NR | 80 (54.8%) | CT at L3 level | OS/PFS |
| Nakamura (2015) | DLBCL | R‐CHOP | 207 | 67 (19–86) | 86 (41.5%) | 115 (55.6%) | CT at L3 level | OS/PFS |
| Nakamura (2019) | AML | Chemotherapy, HCT | 90 | 59 (18–84) | 39 (43.3%) | 39 (43.3%) | CT at L3 level | OS/PFS |
| Rier (2020) | DLBCL | R‐CHOP | 164 | 64.5 (54.3–74) | NR | NR | CT at L3 level | OS/PFS |
| Takeoka (2016) | MM | Bor/IMiD based, aPBSCT | 56 | 71 (65–75) | 37 (66.1%) | 37 (66.1%) | CT or PET/CT at L3 level | OS |
| Williams (2020) | MM | Auto‐HCT | 142 | 62.4 (38.2–78.7) | 50 (35.2%) | 72 (50.7%) | CT at L3 level | OS/PFS |
| Zakaria (2018) | MM‐SM | SBRT | 46 | 64.8 a | 15 (32.6%) | NR | CT at L4 level | OS |
| Zilioli (2021) | HL | Any | 154 | 71 a | 76 (49.4%) | 113 (73.4%) | CT or PET/CT at L3 level | OS/PFS |
a
Mean ages provided only.
chemotherapy, not specified which type; HMA, hypomethylating agents; LSMM, low skeletal muscle mass; NR, not reported; R‐CHOP, rituximab‐cyclophosphamide‐hydroxydaunorubicin‐oncovin‐prednisone; SBRT, stereotactic body radiation therapy.